Bone Marrow News and Research

RSS

Bone Marrow is the soft, sponge-like tissue in the center of most bones. It produces white blood cells, red blood cells, and platelets.

A new method for bone-marrow-derived liver stem cells isolation and proliferation

Great interest has been aroused in the identification and isolation of liver stem cells from bone marrow cells.

15 Apr 2009

Type 1 diabetes controlled by stem cell transplants therapy

Scientists in the United States have found that stem cell transplants enabled people with type 1 diabetes to manage for as long as four years without needing insulin injections and to maintain good glycemic control - such patients typically need daily insulin therapy to control their diabetes.

15 Apr 2009

Three medical centers awarded funds to study generation of cardiac muscle cells

The American Heart Association, with support from the Jon Holden DeHaan Foundation, has awarded funding for three research centers to study the development and mechanisms of generating new cardiac muscle cells.

13 Apr 2009

Transplant program tops in expected one-year survival rate

Fred Hutchinson Cancer Research Center's stem-cell transplant program at the Seattle Cancer Care Alliance (SCCA) was one of only two transplant programs nationwide that consistently outperformed the expected one-year survival rate for unrelated donor transplants, according to an independent report that assessed 122 transplant centers over a five-year period.

12 Apr 2009

Discovery of gene that protects against leukemia

Researchers have identified a gene that controls the rapid production and differentiation of the stem cells that produce all blood cell types -- a discovery that could eventually open the door to more streamlined treatments for leukemia and other blood cancers, in which blood cells proliferate out of control.

9 Apr 2009

Stem cells from bone marrow used to grow new blood vessels

Research led by David Hess of the Robarts Research Institute at The University of Western Ontario has identified how to use selected stem cells from bone marrow to grow new blood vessels to treat diseases such as peripheral artery disease.

6 Apr 2009

Monoclonal antibody cancer therapy

The strategy of using monoclonal antibodies for cancer treatment was first described in the late 1970s with the promise that they could be developed into therapies that were highly specific to cancer cells, killing them with few or no side effects.

6 Apr 2009

New test for a deadly fungal infection in patients with damaged immune systems

A quicker, cheaper and more accurate test for deadly Aspergillus fumigatus fungal infections in patients with damaged or suppressed immune systems was described today, (Thursday 2 April) at the Society for General Microbiology meeting in Harrogate, by Dr Christopher Thornton from the University of Exeter, UK.

1 Apr 2009

Researchers develop mouse models of leukemia that predict response to chemotherapy

Being able to accurately predict how a given cancer will respond to chemotherapy would spare patients with non-responsive tumors the burden of undergoing toxic and ultimately unhelpful treatment.

1 Apr 2009

Amniotic fluid may be a new source of stem cells

For the first time, scientists have shown that amniotic fluid (the protective liquid surrounding an embryo) may be a potential new source of stem cells for therapeutic applications. The study was prepublished online on February 12, 2009, in Blood, the official journal of the American Society of Hematology.

31 Mar 2009

Post heart attack, bone marrow stem cells increase blood flow within heart

Patients treated with their own bone marrow stem cells after a heart attack experienced increased circulation within the heart, a study by Emory University School of Medicine physicians has found.

30 Mar 2009

ArunA Biomedical to commercialize human embryonic stem cell derived mesenchymal cells

ArunA Biomedical, Inc., has announced that it will make its CELL-EZ brand hMC human mesenchymal progenitor cells commercially available to the research community in mid 2009.

29 Mar 2009

Data suggesting that omacetaxine can eradicate leukemic stem cells may offer a breakthrough for CML

Data showing the ability of omacetaxine to kill leukemic stem cells in mouse models with drug-resistant chronic myelogenous leukemia (CML) are the subject of an advance online publication in the journal Leukemia, ChemGenex Pharmaceuticals Limited (ASX:CXS and NASDAQ:CXSP) announced today.

29 Mar 2009

Researchers decipher blood stem cell attachment, communication

Researchers at the National Institutes of Health have deciphered a key sequence of events governing whether the stem cells that produce red and white blood cells remain anchored to the bone marrow, or migrate into the circulatory system.

25 Mar 2009

Stem cell therapy may lead to treatment for deafness

Deafness affects more than 250 million people worldwide. It typically involves the loss of sensory receptors, called hair cells, for their "tufts" of hair-like protrusions, and their associated neurons.

23 Mar 2009

Susceptibility to blood disorders may be inherited

Researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) have shown for the first time that a tendency to develop some blood disorders may be inherited.

15 Mar 2009

Cellular discovery may lead to targeted treatment for rare form of anemia

University of Cincinnati (UC) researchers have identified the specific biological mechanisms believed to lead to a rare and incurable blood disease known as Diamond Blackfan anemia (DBA).

15 Mar 2009

Multiple route bone marrow stem cell injections show promise to treat spinal cord injury

Researchers from DaVinci Biosciences, Costa Mesa, California, in collaboration with Hospital Luis Vernaza in Ecuador, have determined that injecting a patient's own bone marrow-derived stem cells (autologous BMCs) directly into the spinal column using multiple routes can be an effective treatment for spinal cord injury (SCI) that returns some quality of life for SCI patients without serious adverse events.

12 Mar 2009

Study of Rituxan (rituximab) in lupus nephritis misses primary endpoint

Genentech, Inc. and Biogen Idec has announced that a Phase III study of Rituxan (rituximab) plus mycophenolate mofetil (MMF) and corticosteroids in patients with lupus nephritis did not meet its primary endpoint of significantly reducing disease activity at 52 weeks.

11 Mar 2009

'Seeing' stem cells helps in fight against peripheral arterial disease

Interventional radiologists are fitting together the puzzle pieces of how to use stem cells to create new or more blood vessels to treat peripheral arterial disease (PAD) in those individuals with extensively narrowed or clogged arteries.

11 Mar 2009